Related references
Note: Only part of the references are listed.Tumor Volume Doubling Time of Pulmonary Metastases Predicts Overall Survival and Can Guide the Initiation of Multikinase Inhibitor Therapy in Patients With Metastatic, Follicular Cell-Derived Thyroid Carcinoma
Mona M. Sabra et al.
CANCER (2017)
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Bryan R. Haugen et al.
THYROID (2016)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity
M. E. Cabanillas et al.
HORMONES & CANCER (2015)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Protein kinase inhibitor therapy in advanced thyroid cancer: ethical challenges and potential solutions
Keith C. Bible et al.
INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY (2014)
Prognostic Impact of Serum Thyroglobulin Doubling-Time Under Thyrotropin Suppression in Patients with Papillary Thyroid Carcinoma Who Underwent Total Thyroidectomy
Akira Miyauchi et al.
THYROID (2011)
Share Paper
